Apogee Therapeutics, Inc. Common Stock (APGE) — Cash Flow-to-Debt Ratio
Apogee Therapeutics, Inc. Common Stock (APGE) has a Cash Flow-to-Debt Ratio of -1.89x as of December 2025, meaning its operating cash flow of $-62.69 Million could theoretically repay -2% of its total liabilities ($33.25 Million) in one year. See APGE working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Apogee Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for Apogee Therapeutics, Inc. Common Stock across 4 annual periods. Also explore Apogee Therapeutics, Inc. Common Stock (APGE) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Apogee Therapeutics, Inc. Common Stock (2022–2025)
Year-by-year debt coverage analysis for Apogee Therapeutics, Inc. Common Stock. For market capitalisation and broader financial context, see market value of Apogee Therapeutics, Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.84x | $-227.45 Million | $33.25 Million | ▼ -48.5% |
| 2024 | -4.61x | $-171.17 Million | $37.16 Million | ▼ -32.4% |
| 2023 | -3.48x | $-74.76 Million | $21.49 Million | ▼ -111.3% |
| 2022 | -1.65x | $-16.43 Million | $9.98 Million | — |